Peapod Lane Capital LLC Buys New Shares in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Peapod Lane Capital LLC purchased a new position in Kezar Life Sciences, Inc. (NASDAQ:KZR) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 123,994 shares of the company’s stock, valued at approximately $833,000. Peapod Lane Capital LLC owned about 1.70% of Kezar Life Sciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares during the period. XTX Topco Ltd boosted its stake in Kezar Life Sciences by 256.1% during the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after buying an additional 37,504 shares in the last quarter. Ikarian Capital LLC increased its holdings in Kezar Life Sciences by 23.0% in the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after buying an additional 200,000 shares during the period. Finally, Stonepine Capital Management LLC raised its stake in shares of Kezar Life Sciences by 42.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after buying an additional 440,853 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Stock Down 3.3 %

Shares of NASDAQ:KZR opened at $5.90 on Thursday. The business has a fifty day moving average of $6.50 and a 200-day moving average of $6.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. Kezar Life Sciences, Inc. has a twelve month low of $5.20 and a twelve month high of $11.35.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.25. Analysts forecast that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on KZR shares. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 13th. Wells Fargo & Company lowered their price objective on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 19th. Finally, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.